Navigation Links
Heparin Based Nanoscale Materials Developed For Dialysis Treatment

In what can be called as a breakthrough in the field of nanotechnology, researchers have been successful in engineering nanoscale biomaterials, using heparin//, an anticoagulant. These blood compatible could revolutionize medical treatments, including dialysis, a routine form of treatment for renal failure patients.

Furthermore, these medical devices could have numerous diagnostic and therapeutic applications that are not foreseen at the moment.

The researchers prepared several materials with heparin composites or coatings, including carbon nanotubes, nanofibers, and membranes with nanosized pores, and then demonstrated the materials' high compatibility with blood. Heparin is a common therapeutic used to maintain blood flow or prevent clotting during medical procedures and treatments.

The researchers demonstrated the composite heparin membrane with nanopores could work as an artificial kidney, or dialyzer, by filtering the blood and maintaining its flow. The presence of this blood-compatible dialyzer could potentially eliminate the need for systemic administration of heparin to the patient during kidney dialysis, the researchers say.

The heparin-coated membranes are described in a paper titled ‘Ionic Liquid-Derived Blood Compatible Membranes for Kidney Dialysis,’ published online Apr. 24 in advance of print in the Journal of Biomedical Materials Research.

‘These heparin composite membranes and fibers and coated carbon nanotubes are an enabling technology,’ says Saravanababu Murugesan, a recent doctoral graduate in chemical and biological engineering at Rensselaer and lead author of the paper. ‘Our results show these novel materials have great promise in the development of improved medical devices that are blood compatible.’

The research team is led by Robert Linhardt, the Ann and John H. Broadbent Jr. '59 Senior Constellation Professor of Bio
'"/>




Page: 1 2

Related medicine news :

1. Complications In Kidney Failure Patients Linked To Heparin
2. Heparin does not protect from recurrent heart attacks
3. Heparin Antibodies May Put Patients At Risk
4. Ordinary Heparin as Effective as Expensive Blood Thinner
5. Steps To Improve Quality Of Plant-Based Drugs
6. Cancer hazard Found With Animal-Based Nutrients
7. Prime Minister Manmohan Against Incentive-Based Population Control
8. New Oat And Soy-Based Fat Replacer Launched
9. Record Growth Of Soya-Based Dairy Alternatives Over The Past Year In European Markets
10. Race Based Genome Project Launched By Mexico
11. Childhood Asthma Can Be Kept Under Control By Cost-Effective Home Based Interventions
Post Your Comments:
(Date:10/10/2008)...LE, PA The American Nurses Credentialing Center (...) as a Magnet hospital. The news came via a confer...taff who broke out with cheers and applause., GMC...itals and only 294 hospitals in the United States... hospitals are eligible for this recognition., "A...
(Date:10/10/2008)...ggests poor self-care partly to blame , ,...f Medicare beneficiaries who have diabetes, being ... according to a new study. , Publishing in th...l Medicine , researchers from the University of Wa...erage age of 75.6 years) who had diabetes and were...
(Date:10/10/2008)... Honoring excellence in the imple... Healthcare Information and Management Systems Soc...Davies Awards in the Organizational, Ambulatory an... Chicago, IL (PRWEB) October 1...on of electronic health records (EHRs), the Healt...
(Date:10/10/2008)...YORK, Oct. 10 /PRNewswire/ -- The Johns Hopkins Un...ultimedia educational program,"Optimizing Adjuvan...atment,Selection," to present recent key research ...ment., In recent years, advancements in the treat... and biologic treatment combinations that are,incr...
Breaking Medicine News(10 mins):Health News:Geisinger Medical Center earns prestigious Magnet designation 2Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2
...rcises can help restore erectile function in men, ...the University of the West of England in Bristol f...floor exercises had the same overall improvement a...elvic floor is made up of layers of muscle and oth...
...ered a gene mutation that may cause premature ovar...be useful for further study into, what researchers...ovarian failure is a form of infertility that affe...es. It is diagnosed in one out of every 100 women ...
...d allergy -- especially to peanuts -- has been sho...in children. Asthma attacks are the most common re...am Roberts from St. Mary's Hospital in London and ...n treatment, death due to childhood asthma has not...
...lacement therapy dosed to normalize IGF-I levels m...on in a "clinically necessary" weight loss program...ograms is to lose body fat but retain lean body ma... when people go on a diet, after a while, they sto...
Other Medicine News:Health News:Low-dose Growth Hormone (GH) with diet and exercise may help weight loss 2
(Date:10/8/2008)...Review Zanolimumab Program to be Discontinued and ... the Results of its Portfolio Review; Zanolimumab ...educe the Number of ...tCall/ -- Genmab A/S (OMX: GEN),announced today th...(HuMax-CD4(R)). In addition, as a result of a port...
(Date:10/8/2008)... -- Exploratory study shows clinical improvement...sion (PAH), -- Current treatment options have l... progressive and incurable blood vessel disease, ...r treatment of certain cancers, known to inhi... further explore potential of imatinib mesylate in...
(Date:10/7/2008)... Results of FLEXX Trial Presented at the Osteoar...d Congress, PARSIPPANY, N.J., Oct. 7 /PRNewswire/...d results from the FLEXX Trial of Osteoarthritis o...aluronate), a highly pure,non-avian high molecular...A-HA), is superior to intra-articular saline (IA-s...
(Date:10/7/2008)... FORT COLLINS, Colo., Oct. 7 /- A s...amining embryonic stem cell self-renewal,reported...stim (recombinant,human serum albumin) was an effe...ll culture., The article entitled, "The ground st...d that researchers used Cellastim as a recombinant...
Breaking Medicine Technology:Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4RAND study finds increase in piracy and terrorism at sea 3536 1RAND study finds increase in piracy and terrorism at sea 3536 2RAND study finds increase in piracy and terrorism at sea 3536 3Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital Acquired Infections 2329 1Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital Acquired Infections 2329 2Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital Acquired Infections 2329 3Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital Acquired Infections 2329 4Indevus Pharmaceuticals Provides Update on NEBIDO 28R 29 NDA Status 21106 1Indevus Pharmaceuticals Provides Update on NEBIDO 28R 29 NDA Status 21106 2Indevus Pharmaceuticals Provides Update on NEBIDO 28R 29 NDA Status 21106 3Indevus Pharmaceuticals Provides Update on NEBIDO 28R 29 NDA Status 21106 4Indevus Pharmaceuticals Provides Update on NEBIDO 28R 29 NDA Status 21106 5SC Magazine 3A Entrust Entelligence Messaging Server Earns Five Stars and Recommended Rating 3533 1SC Magazine 3A Entrust Entelligence Messaging Server Earns Five Stars and Recommended Rating 3533 2SC Magazine 3A Entrust Entelligence Messaging Server Earns Five Stars and Recommended Rating 3533 3
...CO, Calif., April 03, 2007,/PRNewswire-FirstCall/ ...ed results from its second multi-center Phase 2 tr...h evaluated escalating doses,of the immunotherapy ...prostate cancer (HRPC). Additional follow-up of,th...able to that,being employed in the company,s ongoi...
...(BUSINESS WIRE)--Apr 3, 2007 - Arrowhead Research,...on by its,majority-owned subsidiary Calando Pharma...proliferative effect of the siRNA sequence,selecte...ncer,compound, CALAA-01., The paper, entitled "Pot...ubunit RRM2 Reduce Cell Proliferation In vitro and...
Other Medicine Technology:Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 2Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 3Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 2Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 3
Heavy. 7.5 mm curved tip.
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1.
Size 4 - 2.25 mm
The Catalyst system introduces a new level of computer enhanced precision to microsurgical instrumentation. It has an easy to use digital design with advanced microcomputer control of modules and is
Medicine Products: